Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Sanofi Pasteur Provides Funding To The Human Vaccines Project

XTALKS NEWS

Vaccine

The group’s primary goal is to use knowledge of the immune system to solve problems preventing advancements in vaccines and immunotherapies.

Share this!

January 21, 2016 | by Sarah Massey, M.Sc.

Sanofi’s vaccines unit, Sanofi Pasteur, has agreed to partially fund the Human Vaccines Project – a non-profit, global consortium of researchers and private partners working towards a better understanding of the human immune system. The group’s primary goal is to use knowledge of the immune system to solve problems preventing advancements in vaccines and immunotherapies.

Sanofi Pasteur is proud to join this effort to accelerate and transform vaccine development for major and emerging infectious diseases as well as to better understand human immunology, which may be applicable toward disease management of other chronic disease states,” said Dr. Jim Tartaglia, Sanofi Pasteur's R&D Vice President for New Vaccine Projects. “The Project's partnerships with industrial and non-profit product developers are key to ensuring that technological breakthroughs are rapidly translated into new products.”

Sanofi Pasteur plans to contribute funding to the Human Vaccines Project Research Program, in order to support the coordination and conduction of both the research and administrative activities of the Project. Sanofi Pasteur’s funding will be used to support pilot studies, set up infrastructure, and foster partnerships with key stakeholders.



The Human Vaccines Project has raised $1 billion in the last ten years. It started as a branch of the International AIDS Vaccine Initiative (IAVI), and has received support from industry, academic research organizations, and non-profits to identify and overcome obstacles preventing the development of new vaccines.

Sanofi Pasteur’s R&D Vice President for Translational Science & Biomarkers, Dr. Kent Kester, will act as the company’s representative on the Project’s Industry Advisory Committee. Kester will be responsible for reviewing published and unpublished data, and act as an advisor for the Human Vaccines Project.

“A better understanding of human immunity holds the key to accelerating the vaccine and immunotherapy development for complex global diseases such as HIV, tuberculosis, emerging infectious diseases and cancers,” said Kester. “And since vaccines are among the greatest successes in the history of public health, having led to the eradication of smallpox, near eradication of polio, prevention of 2-3 million deaths per year, and dramatic reductions in human suffering and healthcare costs, the Project makes sense for all of us.”

WATCH & PARTICIPATE IN THESE WEBINARS 


 

The Three Sins of GMP Executives

Cancer Immunotherapy: Advancing and Accelerating Discovery Programs


Keywords: Vaccine, Immunotherapy, Sanofi Pasteur


| NEXT ARTICLE | MORE NEWS |

Share this with your colleagues!

READ THESE NEXT
FDA Highlights Cybersecurity Measures For Medical Device Manufacturers

January 20, 2016 - Earlier this week, the US Food and Drug Administration (FDA) released a draft guidance document detailing measures to be taken by medical device manufacturers, in order to ensure the postmarket cybersecurity of their devices.


French Drug Trial Leaves One Participant Brain Dead, Five Others Seriously Ill

January 19, 2016 - During a Phase I clinical trial run by French drug evaluation company, Biotrial, six participants became critically ill – one of which has now been declared brain dead.


Diabetes Drug Metformin Could Inhibit Progression of Pancreatic Cancer

January 19, 2016 - Researchers at Massachusetts General Hospital believe they have identified the mechanism behind diabetes drug metformin’s ability to stop the progression of pancreatic cancer.

LEAVE A COMMENT
 
Copyright © 2016-2017 Honeycomb Worldwide Inc.